・SELLAS’s Phase 2 clinical trial for its investigational drug SLS009 for acute myeloid leukemia showed positive results. ・Across the treated group, the overall response rate (ORR) reached 46%. ・For ...

Sellas will present new data on its CDK9 inhibitor SLS009 at the American Association for Cancer Research (AACR) meeting on April 21. ・Preclinical findings showed SLS009 triggered leukemia cell death ...

AML related to cancer therapy has been recognized as a distinct clinical entity for more than 40 years. Genetic mutations, ...

New data underscoring the potential of ATNM-400 as a first-in-class Ac-225 radioconjugate with broad pan-tumor efficacy across multiple solid tumor models Actimab-A ...

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced the publication of two abstracts that will be ...

A key cancer-fighting gene in leukemia is switched off—not broken—and scientists from The Jackson Laboratory (JAX) have found ...

A key cancer-fighting gene in leukemia is switched off—not broken—and scientists from The Jackson Laboratory (JAX) found a way to switch it back on.In ...

New data highlight the activity and safety of MRD-guided preemptive azacitidine in patients with myelodysplastic neoplasms or ...

Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and inflammation, then, may hold the keys to ...

Shareholders approve acquisition of Aptose by Hanmi Pharmaceutical in "Go Private" transaction TUS+VEN+AZA triplet frontline therapy continues to demonstrate favorable safety and high rates of efficac ...

Shareholders approve acquisition of Aptose by Hanmi Pharmaceutical in “Go Private” transaction TUS+VEN+AZA triplet frontline therapy continues to ...

A Winter Haven family is navigating an emotional and life-changing medical journey, as two young brothers fight the same rare ...